title: Evaluation of the safety and biodistribution of M032, an attenuated herpes simplex virus type 1 expressing hIL-12, after intracerebral administration to aotus nonhuman primates.
abstract: Herpes simplex virus type 1 (HSV-1) mutants lacking the γ(1)34.5 neurovirulence loci are promising agents for treating malignant glioma. Arming oncolytic HSV-1 to express immunostimulatory genes may potentiate therapeutic efficacy. We have previously demonstrated improved preclinical efficacy, biodistribution, and safety of M002, a γ(1)34.5-deleted HSV-1 engineered to express murine IL-12. Herein, we describe the safety and biodistribution of M032, a γ(1)34.5-deleted HSV-1 virus that expresses human IL-12 after intracerebral administration to nonhuman primates, Aotus nancymae. Cohorts were administered vehicle, 10(6), or 10(8) pfu of M032 on day 1 and subjected to detailed clinical observations performed serially over a 92-day trial. Animals were sacrificed on days 3, 31, and 91 for detailed histopathologic assessments of all organs and to isolate and quantify virus in all organs. With the possible exception of one animal euthanized on day 16, neither adverse clinical signs nor sex- or dose-related differences were attributed to M032. Elevated white blood cell and neutrophil counts were observed in virus-injected groups on day 3, but no other significant changes were noted in clinical chemistry or coagulation parameters. Minimal to mild inflammation and fibrosis detected, primarily in meningeal tissues, in M032-injected animals on days 3 and 31 had mostly resolved by day 91. The highest viral DNA levels were detected at the injection site and motor cortex on day 3 but decreased in central nervous system tissues over time. These data demonstrate the requisite safety of intracerebral M032 administration for consideration as a therapeutic for treating malignant brain tumors.
authors.affiliation: 1 Division of Infectious Diseases, Department of Pediatrics, University of Alabama at Birmingham , Birmingham, AL 35294.
authors.forename: Justin C
authors.initials: JC
authors.lastname: Roth
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Cassady
authors.forename: James J
authors.initials: JJ
authors.lastname: Cody
authors.forename: Jackie N
authors.initials: JN
authors.lastname: Parker
authors.forename: Kathleen H
authors.initials: KH
authors.lastname: Price
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Coleman
authors.forename: James O
authors.initials: JO
authors.lastname: Peggins
authors.forename: Patricia E
authors.initials: PE
authors.lastname: Noker
authors.forename: Nicholas W
authors.initials: NW
authors.lastname: Powers
authors.forename: Sheila D
authors.initials: SD
authors.lastname: Grimes
authors.forename: Steven L
authors.initials: SL
authors.lastname: Carroll
authors.forename: G Yancey
authors.initials: GY
authors.lastname: Gillespie
authors.forename: Richard J
authors.initials: RJ
authors.lastname: Whitley
authors.forename: James M
authors.initials: JM
authors.lastname: Markert
mesh_terms: D000818:Animals; D016645:Aotidae; D001932:Brain Neoplasms / Q000628:therapy; D004333:Drug Administration Routes; D005260:Female; D005910:Glioma / Q000628:therapy*; D018259:Herpesvirus 1, Human / Q000235:genetics*; D057967:Infusions, Intraventricular; D018664:Interleukin-12 / Q000096:biosynthesis / Q000235:genetics*; D008297:Male; D050130:Oncolytic Virotherapy / Q000379:methods*; D014779:Virus Replication
chemical_list: D018664:Interleukin-12